Clinical application of simultaneous detection of cystatin C, cathepsin S, and IL-1 in classification of coronary artery disease

Abstract

Cystatin C, cathepsin S, and IL-1 are three important biomarkers of atherosclerosis. Previous studies emphasized the relationship between individual biomarkers in coronary artery disease (CAD) patients and severity of atherosclerostic lesions of the coronary arteries, while combined cystatin C, cathepsin S, and IL-1 have not been reported for clinical classification of CAD. We aimed to establish a link between cystatin C, cathepsin S, IL-1 and CAD in this cohort study. Totally 112 subjects were enrolled and divided into the stable angina pectoris group, the unstable angina pectoris group and the acute myocardial infarction (AMI) groups, and 50 healthy adults served as controls. The levels of the three biomarkers were detected by ELISA. The results showed that serum level of cystatin C (mg/L) was higher in CAD patients compared with those in the healthy controls (AMIvs. unstable angina pectoris vs. stable angina pectoris vs. controls: 1.27±0.18 vs. 1.09±0.19 vs. 0.91±0.05 vs. 0.78±0.07, all P<0.01). Cathepsin S (ng/mL) was also significantly different among the groups (AMI vs. unstable angina pectoris vs. stable angina pectoris vs. controls: 67.30±8.36 vs. 56.90±7.16 vs. 49.8±2.72 vs. 67.30±8.36, all P<0.01). IL-1 (pg/mL) was significantly different among the groups as well (AMIvs. unstable angina pectoris vs. stable angina pectoris vs. controls: 2.96±0.57 vs. 2.46±0.24 vs. 2.28±0.09 vs. 2.02±0.13, all P<0.01). Spearman's correlation test revealed positive correlation between cystatin C, cathepsin S, IL-1 and Gensini score (r=0.451, 0.491, 0.397, respectively). It is suggested that simultaneous detection of cystatin C, cathepsin S, and IL-1 in serum may be useful in clinical classification and assessment of severity of CAD.

Keywords

cystatin C / cathepsin S / IL-1 / coronary artery disease

References

[1] Murtagh BM, Anderson  HV. Inflammation and atherosclerosis in acute coronary syndromes[J]. J Invasive Cardiol, 2004, 16(7): 377–384.

[2] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(16): 1685–1695.

[3] Libby P. Inflammation in atherosclerosis[J]. Nature, 2002, 420(6917): 868–874.

[4] Siasos G, Tousoulis  D, Kioufis S , Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases[J]. Curr Top Med Chem, 2012, 12(10): 1132–1148.

[5] Nakashima Y, Wight  TN, Sueishi K . Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans[J]. Cardiovasc Res, 2008, 79(1): 14–23.

[6] Iglseder B, Cip  P, Malaimare L , The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men[J]. Stroke, 2005, 36(6): 1212–1217.

[7] Obermajer N, Jevnikar  Z, Doljak B , Role of cysteine cathepsins in matrix degradation and cell signalling[J]. Connect Tissue Res, 2008, 49(3): 193–196.

[8] Hall A, Ekiel  I, Mason RW , Structural basis for different inhibitory specificities of human cystatins C and D[J]. Biochemistry, 1998, 37(12): 4071–4079.

[9] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983, 51(3): 606-606.

[10] Jernberg T, Lindahl  B, James S , Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome[J]. Circulation, 2004, 110(16): 2342–2348.

[11] Deo R, Shlipak  MG, Ix JH , Association of cystatin C with ischemia in patients with coronary heart disease[J]. Clin Cardiol, 2009, 32(11): E18–E22.

[12] Koc M, Batur  MK, Karaarslan O , Clinical utility of serum cystatin C in predicting coronary artery disease[J]. Cardiol J, 2010, 17(4): 374–380.

[13] Ichimoto E, Jo  K, Kobayashi Y , Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction[J]. Circ J, 2009, 73(9): 1669–1673.

[14] Keller T, Messow  CM, Lubos E , Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study[J]. Eur Heart J, 2009, 30(3): 314–320.

[15] Sukhova GK, Shi  GP, Simon DI , Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells[J]. J Clin Invest, 1998, 102(3): 576–583.

[16] Noto D, Cefalu’  AB, Barbagallo CM , Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels[J]. Int J Cardiol, 2005, 101(2): 213–217.

[17] Koc M, Batur  MK, Karaarslan O , Clinical utility of serum cystatin C in predicting coronary artery disease[J]. Cardiol J, 2010, 17(4): 374–380.

[18] Sekizuka H, Akashi  YJ, Kawasaki K , Cystatin C: a better marker to detect coronary artery sclerosis[J]. J Cardiol, 2009, 54(3): 359–367.

[19]   Gan-nanWang, Kai Sun, De-liangHu ,  Hong-hao Wu ,  Xiao-zhi Wang ,  Jin-song Zhang . Serum cystatin C levels are associated with coronary artery disease and its severity[J]. Clinical Biochemistry2014 Jul 30. pii: S0009-9120(14)00530-X. 

[20] Lutgens SP, Cleutjens  KB, Daemen MJ , Cathepsin cysteine proteases in cardiovascular disease[J]. FASEB J, 2007, 21(12): 3029–3041.

[21] Liu J, Ma  L, Yang J , Increased serum cathepsin S in patients with atherosclerosis and diabetes[J]. Atherosclerosis, 2006, 186(2): 411–419.

[22] Koenig W, Twardella  D, Brenner H , Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate[J]. Clin Chem, 2005, 51(2): 321–327.

[23] Hansson GK. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 352(16): 1685–1695.

[24] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol, 2009, 27: 519–550.

[25] Cignarella A. Targeting interleukin-1ß hampers atherosclerosis progression- is there great promise?[J]. [Journal homepage: www.elsevier.com/locate /atherosclerosis]. Atherosclerosis, 2011, 217(1): 64–66.

[26] Kirii H, Niwa  T, Yamada Y , Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2003, 23(4): 656–660

[27] Isoda K, Sawada  S, Ishigami N , Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2004, 24(6): 1068–1073.

[28] Olofsson PS, Sheikine  Y, Jatta K , A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis[J]. Circ J, 2009, 73(8): 1531–1536.

Acknowledgment

This research was founded by science and technology planning project of Xuzhou City (No. KC14SH088). We would like to thank all participants for their technical assistance and advice regarding statistical analysis.

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research. All rights reserved